| Product Name | 20(R)Ginsenoside Rh1 |
|---|---|
| CAS | 80952-71-2 |
| Formula | C36H62O9 |
| MW | 638.87 |
| Appearance | |
| Boiling point | 755.1±60.0 °C | Condition: Press: 760 Torr |
| PKa | 12.91±0.70 | Condition: Most Acidic Temp: 25 °C |
| Product Name | 20(R)Ginsenoside Rh1 |
|---|---|
| CAS | 80952-71-2 |
| Formula | C36H62O9 |
| MW | 638.87 |
| Appearance | |
| Boiling point | 755.1±60.0 °C | Condition: Press: 760 Torr |
| PKa | 12.91±0.70 | Condition: Most Acidic Temp: 25 °C |
| Steamed Panax notoginseng attenuates renal anemia in an adenine-induced mouse model of chronic kidney disease | ||
| Source:SCI：JOURNAL OF ETHNOPHARMACOLOGY | Author:Min Gao | Notes：影響因子：4.36 |
| Reference description | ||
The reference standards of notoginsenoside R1, ginsenosides Rg1, Re, Rb1, Rc, 20(S)–Rh1, 20(R)-Rh1, Rd, Rg6, F4, Rk3, Rh4, 20(S)-Rg3, 20(R)-Rg3, Rk1, and Rg5, all with a purity ≥98%, were purchased from Sichuan Weikeqi Biological Technology Co., Ltd. (Chengdu, Sichuan, China). EPO was purchased from Chengdu Di'ao Jiuhong Pharmaceutical Factory (Chengdu, Sichuan, China). FEJ was purchased from Shandong Dong'e E'jiao Co., Ltd. | ||
